Victrex (VCT) ESG Presentation summary
Event summary combining transcript, slides, and related documents.
ESG Presentation summary
18 Feb, 2026Purpose and strategy
Focus on delivering transformational, sustainable solutions to address global material challenges, with sustainability embedded in core purpose and strategy.
ESG pillars include People (social responsibility), Planet (resource efficiency), and Products (sustainable solutions).
Sustainability strategy aligns with UN Sustainable Development Goals.
Planet: Climate action and resource efficiency
Ambition to achieve net zero by 2050, with interim targets for 2032, covering scopes 1, 2, and 3 emissions.
Science Based Targets Initiative (SBTi) approved, aiming for a 50.4% reduction in scope 1 & 2 emissions by 2032 and 90% by 2050; 30% reduction in scope 3 by 2032.
100% global electricity from renewable sources, increased solar PV usage, and 9% reduction in scope 1 & 2 CO2 emissions since FY 2022.
Continuous improvement programs reduced energy, water, and waste, achieving a 10% reduction in water intensity and over 700 tonnes of CO2 savings in FY 2025.
23% less hazardous waste disposed to landfill compared to FY 2024.
Products: Sustainable solutions and circularity
53% of FY 2025 revenue from sustainable products, with a goal of 70% by 2030.
Life Cycle Analysis shows VICTREX PEEK has lower global warming potential than industry average PEEK.
Products enable significant CO2 savings in automotive, aerospace, and medical sectors, with over 500 million gears and 15 million medical devices using VICTREX polymers.
Investment in sustainable product capacity and development of circularity options to support customer decarbonisation.
Focus on sustainable sourcing, increased recycling rates, and design for recycling and reuse.
Latest events from Victrex
- Q1 2026 volumes and revenue declined, but full-year guidance and cost-saving plans remain on track.VCT
Q1 2026 TU6 Feb 2026 - Q3 volumes up 20% year-over-year, but Medical destocking continues to weigh on profit outlook.VCT
Q3 2024 TU3 Feb 2026 - Volumes up 4%, revenue down 5%, but margin and PBT growth targeted for FY 2025.VCT
H2 202412 Jan 2026 - 12% volume growth, profit down 21%, £10m savings plan, stable outlook and dividends.VCT
H2 20252 Dec 2025 - 16% volume growth and strong cashflow offset by FX and China ramp-up margin pressure.VCT
H1 202520 Nov 2025 - Q3 volume up 8% but revenue down 3% as medical spine weakness and currency headwinds persist.VCT
Q3 2025 TU8 Jul 2025 - Q1 revenue and volume up; full-year outlook steady as mega-programmes and cost controls drive growth.VCT
Trading Update6 Jun 2025